Progress report

Corticosteroids in liver disease: possible mechanisms of action, pharmacology, and rational use

Since the original publications by Hench and his colleagues^{1 2} on the use of cortisone and ACTH in the treatment of rheumatoid arthritis, corticosteroid drugs have assumed an important role in the therapy of a large number of diseases, including diseases of the liver and gastrointestinal tract. Although the precise mode of action of these agents is uncertain, there is increasing evidence that their beneficial effects result from actions on immunological and inflammatory processes. An understanding of such effects and of the clinical pharmacology of the corticosteroid drugs should lead to a more rational approach to therapy. This is particularly important in treating patients with liver disease who are prone to the unwanted effects of corticosteroid therapy and in whom the metabolism of these drugs may be altered.

The aims of this paper are threefold: firstly, to outline the biochemical pharmacology of the corticosteroid drugs relevant to the clinical management of gastrointestinal and liver disease; secondly, to review current knowledge of the immunological and anti-inflammatory effects of these agents; and, thirdly, to discuss the use of prednisone and prednisolone in the management of a number of hepatic diseases. Although the basis of therapy of corticosteroids is probably similar in gastrointestinal and liver diseases, the indications for the use of corticosteroids in gastrointestinal diseases are less clearly defined and are not discussed here.

Pharmacology of corticosteroid drugs

Various biochemical manipulations of the corticosteroid molecule have resulted in differing glucocorticoid or mineralocorticoid activity, but cumulative toxic effects remain the major problem of long-term corticosteroid therapy. Corticosteroids have been shown to interact with receptor proteins in the cytoplasm of cells³ and alteration of protein synthesis follows interaction of the glucocorticoid: receptor complex with nuclear DNA.⁴ However, it has been proposed that corticosteroids have effects on cells that are mediated through other mechanisms. One such mechanism postulates alteration of cell surface characteristics, and this may be responsible for the rapid alterations in lymphocyte kinetics observed after the administration of corticosteroids.⁵ For instance, corticosteroids have been shown to alter the expression of cellular IgG and complement receptors, and the locus of action in these studies appears to be at the membrane level.⁶ Studies using lysosomes also support a direct action at membrane level.⁷ Complex interactions between cyclic nucleotides and glucocorticoids on the physiology of cells have been demonstrated.⁸ Although cAMP does not act as an intracellular 'second message' for the mediation of glucocorticoid action, cortisol

has been shown to activate adenyl cyclase in human leucocytes^{9 10} and this may have a significant influence on the state of activation of these cells, especially those of the monocyte/macrophage system.¹¹

Prednisone has very little intrinsic glucocorticoid activity,¹² and has to be converted in the liver to the biologically active metabolite, prednisolone. In severe liver failure some impairment of this conversion may occur, but it is comparatively trivial.¹³ In a detailed pharmacokinetic study, Schalm and his colleagues¹³ showed that serum prednisolone levels were significantly lower in patients with impaired liver function than in others, but there was also a greater percentage of pharmacologically active, unbound drug present in the serum under such circumstances. An additional factor to be taken into account in this situation is impairment of hepatic A ring reduction, resulting in decreased elimination of the active metabolite.^{14 15} Thus, impaired conversion of prednisone to prednisolone in severe liver failure may be compensated for by a decreased rate of elimination of the active metabolite as well as by decreased protein binding.

Schalm and his colleagues concluded that failure of some patients with chronic hepatitis to respond to prednisone treatment could not be attributed to the small differences in conversion of prednisone to prednisolone associated with severe impairment of liver function. However, there are occasional individuals who show a marked impairment in the conversion of prednisone to prednisolone,¹⁴ and most authors accept that it is probably best to administer prednisolone rather than prednisone to all patients with liver disease, if only because the serum levels achieved are more predictable.

The elimination half-life of prednisolone from plasma remains constant (3.5 ± 0.2 h) over the conventional dosage range (5–100 mg) and this closely correlates with the tissue half-life which is approximately one and a half to twice the plasma elimination half-life.¹⁶ It is the tissue half-life which most closely relates to therapeutic efficacy and long-term toxic effects.¹⁶ Absorption of prednisolone appears to be virtually complete even in the presence of mucosal damage¹⁷ or when administered concurrently with antacid medications.¹⁸ Over the conventional dosage range, protein binding is unchanged with a constant amount bound to cortisol binding globulin (CBG), most of the remaining prednisolone being bound loosely to other serum proteins with approximately 10% prednisolone unbound. In hypoalbuminaemic states a greater proportion of prednisolone is unbound and this may result in severe metabolic consequences.¹⁹ This has led some workers to derive a formula for adjusting prednisolone dose on the basis of serum protein levels.²⁰ As the appropriate dose is arbitrary and difficult to predict, this further refinement seems unnecessary. It should be noted that the binding affinity of the prednisolone for the intracellular glucocorticoid receptor is very much higher than that for albumin and probably that proportion not bound to CBG is metabolically active, not merely the free drug.⁸ A recent publication has shown that the glucocorticoid fraction in plasma that is available for transport is not restricted to the free fraction, but includes the larger albumin-bound moiety.²¹ It has also been observed by different workers^{22 23} that alterations in the metabolic clearance rate of corticosteroids can have an influence on the therapeutic effect and it has been suggested that long-term daily therapy with corticosteroids results in the induction of corticosteroid metabolism and consequent loss of effect.²² This effect, if present, is likely

to be slight and to have little influence on therapy. It has, however, been shown that simultaneous administration of potent microsomal enzyme-inducing drugs such as diphenylhydantoin,²⁴ phenobarbitone,²⁵ or rifampicin²⁶ can result in a marked increase in the metabolic clearance of prednisolone with consequent loss of therapeutic effect. Other drugs with a similar enzyme-inducing potential are likely to have a similar influence on prednisolone kinetics.

Anti-inflammatory effects and changes in immune system mediated by corticosteroids

Corticosteroids cause a wide variety of anti-inflammatory effects and changes in the immune system. These are considered here before a discussion of the clinical use of these agents in specific diseases. As there is considerable overlap between anti-inflammatory and anti-immune effects, these are considered together here. With respect to the immune system, most of our current knowledge indicates that it is chiefly cell-mediated immune function rather than the humoral components of the defence mechanisms that are altered by corticosteroid therapy. After the administration of corticosteroids, there is a blood neutrophil leucocytosis that reaches a peak four to six hours after the drug has been given.²⁷ At the same time, there is a decrease in the circulating numbers of lymphocytes,²⁸ monocytes,²⁹ and eosinophils.³⁰ The depletion in circulating numbers of monocytes, lymphocytes, and eosinophils is transient and counts return to normal after 24 hours except after single massive doses of methylprednisolone³¹ (> 1g). This pattern is not peculiar to isolated single doses of corticosteroids but occurs on a daily or alternate-day basis for as long as several years.³² Hence, the cytopenia is not cumulative; the kinetics are related to each administration of corticosteroids, except when the dosage interval is less than 24 hours.

With regard to neutrophil function, the most important effect is the inhibition of their ability to accumulate at an inflammatory focus³³ this is a result of inhibition of chemotaxis³⁴ and of inhibition of leucocyte adherence to blood vessel walls.³⁵ Neutrophils from patients receiving corticosteroids demonstrate normal phagocytic and bactericidal functions,⁵ although very high concentrations of corticosteroids can suppress these functions also. Monocyte chemotaxis is similarly impaired in the presence of corticosteroids³⁶ although monocytes isolated from subjects on corticosteroids exhibit normal chemotactic responses *in vitro*.²⁹ Monocyte bactericidal activity is depressed by corticosteroids.²⁹ However, the most important aspect of monocyte function that is altered by corticosteroids is their ability to respond to lymphokines. These are chemical messengers liberated by lymphocytes on exposure to certain antigens and mitogens, and they modify the behaviour and recruitment of other cells involved in the immune response. Some of the most important lymphokines identified alter monocyte activity such as migration inhibition factor (MIF), macrophage arming factor (MAF) and macrophage chemotactic factor (MCTF). There is evidence that, in general, lymphokine production is uninfluenced by corticosteroids,^{37 38} although some work suggests that corticosteroids can depress the production of certain lymphokines, in particular macrophage chemotactic factor.³⁹ However, the ability of monocytes to respond to liberated lymphokines is markedly suppressed.^{37 38} This may be mediated by alterations in the surface

receptors of the monocyte.

As indicated above, corticosteroid administration causes a transient lymphocytopenia with counts returning to normal by 24 hours.²⁸ There is a decrease in both T and B lymphocyte numbers, although there is a disproportionately greater decrease of circulating T lymphocytes.²⁸ This depletion almost certainly represents redistribution into other body compartments rather than lysis.⁴⁰ Some subpopulations of lymphocytes may show differing sensitivities to corticosteroids, as it has been shown that circulating 'null' cells (lymphocytes with neither E nor EAC surface markers) are not decreased after prednisone administration.⁴¹ It has also been noted that there are differential effects of different corticosteroid preparations on lymphocyte function. For instance, dexamethasone administration results in suppression of PHA-induced cellular cytotoxicity when lymphocytes are assessed four hours after administration; yet equivalent 'anti-inflammatory' doses of prednisone or hydrocortisone fail to produce this suppression.⁴¹ This may reflect the different plasma half-lives and different receptor affinities of the various preparations.⁴¹ Lymphocyte responses to antigen (purified protein derivative of *M. tuberculosis*, PPD) are suppressed only during chronic administration of corticosteroids.⁴² Mitogen (phytohaemagglutinin, pokeweed mitogen, concanavalin A) responses appear to be unaltered.⁴² Conflicting results on these responses⁴³ may have represented a profound depletion of monocytes necessary for the *in vitro* response to antigens. Although macrophage migration inhibiting factor (MIF) and macrophage arming factor (MAF) are released normally by lymphocytes, the monocyte-macrophage response to these liberated factors is impaired in the presence of corticosteroids.^{37 38} One illustrative consequence of this may be the reduction of delayed skin reactivity in patients on corticosteroids. Additional effects of corticosteroids that have been demonstrated include impairment of particulate antigen processing by macrophages,⁴⁴ and diminution of T lymphocyte cytotoxic activity by prior exposure of these cells to corticosteroids.⁴⁵ This latter effect has been shown to be independent of RNA, DNA, or protein synthesis and is reversed by subsequent exposure to concanavalin A. This suggests that the site of action of corticosteroids in this situation is at the membrane level, being independent of glucocorticoid receptor interaction.

In summary, the circulation kinetics and access of leucocytes to sites of potential immunological reactions are suppressed and the interaction of effector cells with the soluble products of activated lymphocytes are antagonised, resulting in marked suppression of cell-mediated immune responses. The influences of corticosteroids on monocytes and lymphocytes are sum-

Table 1 *Influence of corticosteroids on lymphocyte and monocyte function*

	Recognised effects	Probable effects
Monocytes and macrophages	Decreased numbers in circulation ³⁹	Antigen processing inhibited ⁴⁴
	Decreased access to inflammatory sites ⁴⁶	Decreased response to chemotactic factors ³⁶
	Decreased bactericidal capacity ³⁹	Lysosomal stabilisation ³⁸
	Decreased reticuloendothelial system clearance ⁴⁷	
Lymphocytes	Decreased response to MIF and MAF ³⁷	
	Reduced circulating numbers ³⁸	Normal mitogen responses ⁴³
	Decreased antigen blastogenesis ^{48 43}	Inhibition of release of MCTF ³²
	Normal release of MIF and MAF ³⁸	
	Reduction of T cell cytotoxicity ⁴⁵	

MIF: migration inhibitory factor. MAF: macrophage arming factor. MCTF: macrophage chemotactic factor.

marised in Table 1.

Antibody synthesis is not influenced by corticosteroids, although this does depend on the timing of corticosteroid administration in relation to the antigenic challenge. With the exception of high doses of methylprednisolone, serum immunoglobulin concentrations are not altered.⁴⁹ All complement component serum levels may be reduced to a variable degree by corticosteroid therapy.⁵⁰

Some actions of corticosteroids are predominantly anti-inflammatory, such as their influence on vascular permeability,⁵¹ and their alteration of the response to local mediators of inflammation such as kinins⁵² and histamine,⁴⁸ but other influences are predominantly immunosuppressive (Table 2).

Table 2 *Anti-inflammatory and immunosuppressive effects of corticosteroid therapy*

<i>Predominantly anti-inflammatory effect</i>	<i>Predominantly immunosuppressive effect</i>
Vascular stabilisation ⁴¹	Decreased complement levels ⁵⁰
Altered responsiveness to kinins ⁵² and histamine ⁴⁸	Monocytopenia, ⁴⁹ eosinopenia ⁵⁰
Decreased neutrophil accumulation ^{33 34 35}	Lymphocytopenia ⁴⁸
Decreased neutrophil function ⁵	Decreased lymphocyte and monocyte function (Table 1)

Although immunosuppressive activity may result in anti-inflammatory activity, the importance of either influence remains to be elucidated in many disease states.

A separate effect that may have some relevance in human liver disease is the suppression of collagen formation by inhibition of proline hydroxylase activity.⁵⁴ Although this has been demonstrated in experimental liver injury, no studies to date have shown that this is of significant clinical benefit to man.

With regard to hepatitis, the role of infiltrating mononuclear cells as the cause of cell death has been pursued in a number of studies. Lymphocyte cytotoxicity for a variety of liver cell lines in tissue culture has been demonstrated in chronic active liver disease (CALD), although this has not been shown to be a specific finding (see review by Smith, C.J. *et al.*⁵⁵) However, it does seem likely that lymphocytes from patients with a variety of liver disorders are sensitised to one or more antigens found in normal liver tissue. Lymphocytes from patients with alcoholic hepatitis have shown '*in vitro*' cytotoxicity for rabbit hepatocytes, possibly reflecting sensitivity to a liver-specific membrane lipoprotein.⁵⁶ It may therefore be relevant that corticosteroids have been shown to diminish lymphocyte cytotoxic activity.⁴⁵

A recent paper has provided evidence that mononuclear phagocytes already recruited into the liver by other processes may release factors toxic for hepatocytes on exposure to endotoxin, thus perpetuating tissue injury.⁵⁷ The ability of endotoxin to activate macrophages in this situation may be reduced by corticosteroids, as these drugs have been shown to protect against endotoxin-induced shock.⁵⁸ Thus it may be appreciated that corticosteroid therapy in liver disease may influence the course of the illness through a wide variety of anti-inflammatory and immune mechanisms, and, until precise knowledge of the pathogenesis of these diseases is apparent, the mechanism of action of corticosteroids remains speculative.

Effect of prednisolone on normal hepatic function and tests of liver function

In the hepatic conditions to be considered, the influence of prednisolone on the course of the illness has been judged either on clinical grounds or on the basis of changes in biochemical tests. This latter area has been investigated in normal subjects,⁵⁹ and, although there was a significant decrease in the conjugated bilirubin concentration during prednisolone treatment, there was no alteration in quantitative tests of liver function (galactose elimination capacity, bromsulphthalein transport maximum and storage capacity). There was a significant rise in GPT and IgM concentrations, but no value became abnormal. All other enzymes and serum proteins remained unchanged during prednisolone therapy. Urinary D-glucaric acid output also remained unchanged, suggesting that prednisolone had little effect on the state of hepatic enzyme induction. Although caution should be exercised in extrapolating these results to patients with chronic liver disease, they show that prednisolone administration does not appear to interfere with the interpretation of these tests.

Use of corticosteroids in liver disease

VIRAL HEPATITIS

As early as 1937, it was suggested by Eppinger that adrenal cortical hormones might be beneficial in the treatment of hepatic diseases. Initial studies of the use of corticosteroids in viral hepatitis indicated that they might be of some benefit,⁶⁰⁻⁶¹ but as early as 1953 it was suggested that this form of therapy made the patient more vulnerable to relapse.⁶² Of 117 control patients, none relapsed, whereas two of 10 patients treated with cortisone relapsed. Although these figures are unbalanced and retrospective, this study has been subsequently confirmed in a paper from Switzerland, where a relapse rate of 15% was noted in the steroid-treated group (101 subjects) as against 1% in the placebo group (275 subjects).⁶³ In addition, the steroid-treated group were more prone to peptic ulceration and pyogenic infections. A feature of all these early studies was the more rapid resolution of raised serum levels of bilirubin in the steroid-treated groups. A case has been made by a number of authors for the treatment with corticosteroids of viral hepatitis with prolonged cholestasis as the period of jaundice is shortened. The opposing view has been expressed, but review of the biochemistry and histology of the patients in this report⁶⁶ suggests that at least two of the four patients studied had chronic active hepatitis. Relapses are likely if the steroids are withdrawn too soon and treatment, if instigated, should be continued well into convalescence and until the serum bilirubin level is normal.⁶⁴ With the exception of prolonged cholestasis, corticosteroids are contraindicated in uncomplicated viral hepatitis.⁶⁷

FULMINANT HEPATITIS

There has been considerable controversy over the years concerning the place of corticosteroids in the management of fulminant hepatic failure. In 1962 it was reported that corticosteroids might have a favourable influence on the outcome of patients with acute hepatitis in coma,⁶⁸ but other reports were unable to confirm these findings.⁶⁹⁻⁷¹ In 1976 a double-blind prospective study of the use of methylprednisolone in severe viral hepatitis was published and the authors concluded 'that corticosteroid therapy did not enhance

survival in patients with severe viral hepatitis and that it may be detrimental⁷². In the ensuing correspondence there was some criticism of the comparability of the two groups and of the fact that survival in the placebo group was over 80%.⁷³ This figure suggests that these were not patients with fulminant hepatitis but that they had a less severe form of hepatitis. However, other correspondence has provided additional figures on survival in other groups of patients with support for the contention that corticosteroids are of no value in fulminant hepatitis.⁷¹ The likelihood of a type II statistical error in this study⁷² is very small indeed. In a preliminary report from the USA Acute Hepatic Failure Study Group,⁷⁴ no benefit for corticosteroid therapy has been demonstrated after analysis of the results from the first 57 patients randomised and considered eligible. A smaller unblinded, European multicentre study⁷⁵ has produced similar results. Survival was 12% in the corticosteroid-treated group (26 subjects) compared with 14% in the placebo group (14 subjects). Although there are differences in disease severity, entry criteria, and therapy in all these studies, the general consensus at present is firmly against the use of corticosteroids in fulminant hepatitis. Indeed, combining results from the four randomised trials^{70 71 72 75} gives strong evidence of a negative effect ($P < 0.02$).

CHRONIC ACTIVE HEPATITIS

There have been three major studies published in the past 10 years demonstrating a beneficial effect of corticosteroids in chronic active hepatitis (CAH), both in terms of disease activity and of mortality.⁷⁶⁻⁷⁸ Unfortunately, the meaning of the term 'chronic active hepatitis' has evolved since the instigation of these studies, and current criteria are still not uniformly accepted. What was originally a clinical term referring to symptomatic patients with both chronic and active hepatocellular disease has now become a term applied on the basis of characteristic hepatic histological features, whatever the clinical context. We are also aware of a number of predisposing factors, especially certain drugs, that were not apparent 15 years ago.

In chronic active hepatitis, a number of abnormalities of cell-mediated immunity (CMI) have been documented (see review⁵⁵). These include sensitivity to crude liver homogenates, and to more highly purified liver antigens such as human liver-specific protein (LSP or HSP).^{79 80} Lymphocyte cytotoxicity to liver cells in tissue culture has been demonstrated, although this is not specific for chronic active hepatitis. These changes in cell-mediated immunity may parallel disease activity,⁸¹ and it is tempting to suggest that the beneficial effect of corticosteroids is mediated through their known effects on cell-mediated immunity. It should be noted that it has been postulated that poor CMI responses to HBsAg may result in HBsAg persistence (the chronic carrier state), a normal response resulting in acute hepatitis and HBsAg clearance.⁸² If this is correct, early exhibition of corticosteroids in HBsAg-positive hepatitis might result in chronic disease and a protracted carrier state. However, this has never been convincingly demonstrated to occur in human disease. It has been stated that HBsAg-positive disease runs a more benign course and responds to corticosteroid therapy less frequently, and a recent abstract supports this contention.⁸³

The Mayo Clinic has reported that two-thirds of a group of patients with CAH being treated with steroids suffered one or more serious complications

of steroid therapy.⁸⁴ It therefore seems that those patients in whom the benefits of steroid therapy outweigh the incidence of serious side effects need to be precisely defined.

It should be noted that, of the three widely quoted trials,⁷⁶⁻⁷⁸ only two were able to test for HBsAg and that the incidence of this marker was surprisingly low, probably reflecting the relatively insensitive methods of detection available at the time. In the quoted trials, and especially the Mayo Clinic study, a large number of patients were symptomatic and a large proportion were cirrhotic at the time of entry to the study. In addition, the biochemical abnormalities required for entry to this study showed that this group had particularly severe disease (AST $10 \times$ normal or AST $5 \times$ normal, together with a serum γ globulin level $2 \times$ normal). This is in contrast with the present situation, where a substantial proportion of patients diagnosed as having CAH are asymptomatic⁸⁵ and pre-cirrhotic with less markedly abnormal biochemical parameters.

However, all of the above three studies of corticosteroid therapy of patients with CAH arrived at similar conclusions, and in an elegant analysis of these studies Wright *et al.* come to the conclusion 'that corticosteroid therapy only outweighs its potential toxicity in those who are symptomatic, who are HBsAg-negative and who have severe histological abnormalities (subacute hepatitis with multilobular necrosis or active cirrhosis)'.⁸⁶ The risk to benefit ratio is unknown in patients who are HBsAg-positive or clinically well persons and routine administration of corticosteroids to these subgroups may not be justified. However, each patient needs to be assessed on an individual basis, as there may well be a number of patients in these categories who benefit from steroid therapy.

In those patients with chronic active hepatitis who benefit from steroid therapy, it has been shown that a daily combination of prednisone (10 mg) and azathioprine (50 mg) after an initial month of higher prednisone dose offers the best chance of disease control combined with the lowest incidence (10%) of major steroid side-effects.⁸⁴ Current advocacy of alternate day steroid regimes has led to their assessment in this condition. Titration of alternate day dosage to secure biochemical and clinical resolution does increase early survival, but the incidence of severe complications is considerably higher (36%) than in the group treated with the fixed combination outlined above.⁸⁴ In addition, histological resolution of the disease occurred less frequently in the 'alternate day' treated patients. A recent study recommends the use of prednisolone rather than prednisone, as the serum levels are more predictable.¹⁴

Relapse tends to be treated in an empirical manner, and additional studies are necessary to determine the appropriate use of corticosteroids in this situation. However, it has been shown that 50% of those with severe disease will relapse if corticosteroids are discontinued within six months of remission induction, whereas the relapse rate falls to 8% if treatment is continued beyond six months.^{84 87} It seems that only a minority require continuous steroid therapy for longer than three years,⁸⁸ but guidelines have still to be precisely determined.

Late results of the outcome of treatment with corticosteroids of an early group of patients have recently been published by the Royal Free group in abstract form.⁸⁹ The mean duration of treatment with corticosteroids was 4.5

years. Age, presence of antinuclear factor, cirrhosis, or level of transaminases at presentation were not prognostic factors, although male patients untreated did less well than female patients. Ten-year survival in the treatment group was 63%, compared with 27% in the control group ($P=0.03$) with a median survival of 12.2 years in the former group, compared with 3.3 years in the latter.

CHRONIC PERSISTENT HEPATITIS

There is general agreement that corticosteroid therapy is not indicated in those patients with chronic persistent hepatitis, as the condition is virtually asymptomatic, non-progressive, and associated with a good prognosis.⁹⁰ However, sampling error on liver biopsy can lead to an erroneous diagnosis in a patient with chronic active hepatitis. Regular follow-up should be encouraged, especially for symptomatic patients, those with transaminase concentrations greater than five times normal, and those with serum markers of past or present hepatitis B infection. Progression of chronic persistent hepatitis to chronic active hepatitis has been documented especially in those patients presenting with symptoms of insidious onset and with markers of past or present hepatitis B infection.⁹¹ The use of corticosteroids in this situation is unlikely to be of clinical benefit, both because of the relative mildness of the illness and because of the association with markers of hepatitis B infection.⁸³⁻⁸⁶ In the two subjects treated with corticosteroids in the study quoted above,⁹¹ no histological change had been observed after a year's treatment.

ALCOHOLIC LIVER DISEASE

Investigations into the short-term use of corticosteroids in alcoholic liver disease have been concerned with the syndrome of alcoholic hepatitis, partly because of the high mortality (40%) and partly because patients with this condition demonstrate various immunological abnormalities that may be responsive to corticosteroid treatment. It has been demonstrated that circulating T lymphocytes from patients with alcoholic hepatitis react to alcoholic hyaline⁹² and show *in vitro* cytotoxicity to rabbit hepatocytes.⁵⁶ There is also a reversible depression of delayed cutaneous hypersensitivity in alcoholic hepatitis.⁹³ These alterations in immunological reactivity suggest a rational basis for corticosteroid therapy. It has been proposed that corticosteroids might shorten the duration of the illness, reduce the mortality and the incidence of subsequent cirrhosis. A large number of clinical trials have been published⁹⁴⁻¹⁰¹ and almost all have shown no significant benefit in terms of mortality, although various biochemical measures improved more rapidly on steroid therapy. Two of these studies^{95,99} demonstrated a benefit with the administration of corticosteroids and further analysis of this suggests that there might be a subgroup of patients with alcoholic hepatitis who do benefit from the administration of corticosteroids. It seems that this group is represented by those with clinical criteria suggestive of the diagnosis of alcoholic hepatitis who also have either hepatic encephalopathy or a coagulation disorder precluding liver biopsy. In one trial published⁹⁶ that has studied this particular subgroup, only 20 patients were randomised, and although there was a trend to better survival in the steroid-treated group, no statistical difference was noted. There is a high degree of probability of a type II error

in this particular study. Another trial studying this subgroup shows a definite advantage for the steroid-treated group.⁹⁹ Conn, in an editorial on the subject,¹⁰² has outlined the various pitfalls in either the randomisation procedures, the exclusion process, or the experimental design, all of which might have led to unwanted bias in the interpretation of the results. In this editorial, Conn states that there was no evidence to support the use of corticosteroids in the routine treatment of alcoholic hepatitis, but that there may be a subgroup with severe alcoholic hepatitis and encephalopathy who may benefit. Data extracted from the published studies on the relevant subgroup suggests a definite advantage (see review by Tolman and Powell),¹⁰³ but until a large randomised double-blind study has been completed and published the answer remains uncertain. There is general agreement that steroids are of no benefit in those patients with only mild to moderate disease—that is, without encephalopathy.

It has been stated that, in those who have been treated with steroids, a course of high-dose steroid therapy (40–60 mg prednisolone daily) lasting four to six weeks is sufficient, with gradual reduction of the dose after this time. If a short-term benefit is convincingly demonstrated, the uncertainty that remains is that in those patients treated with steroids there is the possibility that steroid therapy merely delays the patient's eventual death. One study has commented on the high incidence of mortality in the steroid-treated group after completion of the study.¹⁰⁰ The scanty evidence available on the development of cirrhosis suggests that steroid therapy has no influence on the eventual development of this complication.

Miscellaneous liver diseases

Because of the known immune associations with primary biliary cirrhosis, corticosteroids have been used in this condition. However, no convincing benefit has been demonstrated,¹⁰⁴ and, indeed, the skeletal effect of corticosteroids, together with the known incidence of osteomalacia and osteoporosis in this disease¹⁰⁵, contraindicates them.

Granulomatous hepatitis is a curious entity¹⁰⁶ that is usually a diagnosis of exclusion, although more causes of hepatic granulomata are being recognised. The association of a chronic febrile illness with hepatic granulomata in the absence of a known cause is often designated granulomatous hepatitis. In some patients it may represent an atypical form of sarcoidosis.¹⁰⁷ Dramatic clinical and biochemical responses to corticosteroid therapy have been noted and alternate-day therapy appears to maintain control successfully.¹⁰⁸ This is a rare condition and the small numbers in the studies published do not allow more specific guidelines.

Corticosteroids are of benefit in those multi-system diseases that occasionally involve the liver, such as polyarteritis nodosa or systemic lupus erythematosus. Corticosteroids have been used in Wilson's disease, Gilbert's disease, Dubin Johnson syndrome, and hepatic amyloidosis and have been shown to be of no value.

Summary of clinical use of corticosteroid drugs in liver disease

The pharmacokinetics of corticosteroids are similar over a wide dosage range, and although there are minor variations in conversion of prednisone to prednisolone in severe liver disease this is unlikely to alter therapeutic

efficacy. Prednisolone administration, however, results in more predictable serum levels. Enzyme-inducing agents, in particular diphenylhydantoin, phenobarbitone, and rifampicin, may markedly reduce the therapeutic efficacy of steroids.

There is an established place for steroid therapy in the management of the symptomatic and histologically severe forms of chronic active hepatitis. However, the use of corticosteroids in hepatitis B-positive CAH is still controversial. Corticosteroids are of no benefit in fulminant hepatitis, whatever the aetiological agent, and may well be detrimental in this situation. If they have a place in the management of alcoholic liver disease, it will be confined probably to those patients with alcoholic hepatitis who have encephalopathy or a severe coagulation disorder. There is a very limited role for their use in viral hepatitis with prolonged cholestasis, although there is an increased risk of relapse with this therapy. Corticosteroids often have a dramatic effect on patients with granulomatous hepatitis, but in a large variety of other hepatic diseases they have been demonstrated to be of no benefit.

*Address for reprint requests:
Professorial Medical Unit,
Level F, Centre Block,
Southampton General Hospital,
Southampton, SO9 4XY, England

*A. R. TANNER AND L. W. POWELL
Department of Medicine
University of Queensland
Royal Brisbane Hospital
Brisbane
Australia 4029

Received for publication 2 October 1979

References

- ¹Hench, P. S., Kendall, E. C., Slocumb, C. H., and Polley, H. F. (1949). The effect of a hormone of the adrenal cortex (17-hydroxy-11 dehydro-corticosterone: compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis: preliminary report. *Proceedings of the Staff Meetings, Mayo Clinic*, **24**, 181–185.
- ²Hench, P. S., Kendall, E. C., Slocumb, C. H., and Polley, H. F. (1950). Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. *Archives of Internal Medicine*, **85**, 545–666.
- ³Rousseau, G. G., Baxter, J. D., and Tomkins, G. M. (1972). Glucocorticoid receptors: relations between steroid-binding and biological effects. *Journal of Molecular Biology*, **67**, 99–115.
- ⁴Baxter, J. D., Rousseau, G. G., Benson, M. C., Garcea, R. L., Ito, J., and Tomkins, G. M. (1972). Role of DNA and specific cytoplasmic receptors in glucocorticoid action. *Proceedings of the National Academy of Science*, **69**, 1892–1896.
- ⁵Fauci, A. S., Dale, D. C., and Balow, J. E. (1976). Glucocorticosteroid therapy: mechanisms of action and clinical considerations. *Annals of Internal Medicine*, **84**, 304–315.
- ⁶Schreiber, A. D., Parsons, J., McDermott, P., and Cooper, R. A. (1975). Effect of corticosteroids on the human monocyte IgG and complement receptors. *Journal of Clinical Investigation*, **56**, 1189–1197.
- ⁷Weissmann, G., and Thomas, L. (1963). Studies on lysosomes. II. The effect of cortisone on the release of acid hydrolases from a large granule fraction of rabbit liver induced by an excess of Vitamin A. *Journal of Clinical Investigation*, **42**, 661–669.

- ⁸Thompson, E. B., and Lippman, M. E. (1974). Mechanism of action of glucocorticoids, *Metabolism*, **23**, 159–202.
- ⁹Logsdon, P. J., Middleton, E. Jr., and Coffey, R. G. (1972). Stimulation of leukocyte adenylyl cyclase by hydrocortisone and isoproterenol in asthmatic and non-asthmatic subjects. *Journal of Allergy and Clinical Immunology*, **50**, 45–56.
- ¹⁰Parker, C. W., Huber, M. G., and Baumann, M. L. (1973). Alterations in cyclic AMP metabolism in human bronchial asthma. III. Leukocyte and lymphocyte responses to steroids. *Journal of Clinical Investigation*, **52**, 1342–1348.
- ¹¹Gallin, J. I., Sandler, J. A., Clyman, R. I., Manganiello, V. C., and Vaughan, M. (1978). Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. *Journal of Immunology*, **120**, 492–496.
- ¹²Ballard, P. L., Carter, J. P., Graham, B. S., and Baxter, J. D. (1975). A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. *Journal of Clinical Endocrinology and Metabolism*, **41**, 290–304.
- ¹³Schalm, S. W., Summerskill, W. H. J., and Go, V. L. W. (1977). Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. *Gastroenterology*, **72**, 910–913.
- ¹⁴Davis, M., Williams, R., Chakraborty, J., English, J., Marks, V., Ideo, G., and Tempini, S. (1978). Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. *British Journal of Clinical Pharmacology*, **5**, 501–505.
- ¹⁵Powell, L. W., and Axelsen, E. (1972). Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. *Gut*, **13**, 690–696.
- ¹⁶Meikle, A. W., and Tyler, F. H. (1978). Potency and duration of action of glucocorticoids. *American Journal of Medicine*, **63**, 200–207.
- ¹⁷Tanner, A. R., Caffin, J. A., Halliday, J. W., and Powell, L. W. (1978). Pharmacokinetics of prednisolone in chronic liver disease, coeliac disease and Crohn's disease (Abstract). *Australian and New Zealand Journal of Medicine*, **8**, 558.
- ¹⁸Tanner, A. R., Caffin, J. A., Halliday, J. W., and Powell, L. W. (1979). Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. *British Journal of Clinical Pharmacology*, **7**, 397–400.
- ¹⁹Lewis, G. P., Jusko, W. J., Burke, C. W., and Graves, L. (1971). Prednisone side effects and serum protein levels. A collaborative study. *Lancet*, **2**, 778–781.
- ²⁰Uribe, M., Centeno, F., and Robles, G. (1978). How to adjust prednisone-prednisolone dosage in patients with liver disease and hypoalbuminaemia (Abstract). *Gastroenterology*, **74**, 1155.
- ²¹Pardridge, W. M. and Mietus, L. J. (1979). Transport of steroid hormones through the rat blood-brain barrier. *Journal of Clinical Investigation*, **64**, 145–154.
- ²²Kowozar, M., Veatch, L., and Kaplan, M. M. (1974). Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. *Journal of Clinical Endocrinology and Metabolism*, **38**, 407–412.
- ²³Meikle, A. W., Clarke, D. H., and Tyler, F. H. (1976). Cushing syndrome from low doses of dexamethasone. *Journal of the American Medical Association*, **235**, 1592–1593.
- ²⁴Petereit, L. B., and Meikle, A. W. (1978). Effectiveness of prednisolone during phenytoin therapy. *Clinical Pharmacology and Therapeutics*, **22**, 912–916.
- ²⁵Brooks, S. M., Werk, E. E., Ackerman, S. J., Sullivan, I., and Thrasher, K. (1972). Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. *New England Journal of Medicine*, **286**, 1125–1128.
- ²⁶Buffington, G. A., Dominguez, J. H., Piering, W. F., Hebert, L. A., Kauffman, H. M., and Lemann, J. Jr. (1976). Interaction of rifampicin and glucocorticoids. *Journal of the American Medical Association*, **236**, 1958–1960.
- ²⁷Dale, D. C., Fauci, A. S., Guerry, D., IV, and Wolff, S. M. (1975). Comparison of agents producing a neutrophilic leukocytosis in man. *Journal of Clinical Investigation*, **56**, 808–813.
- ²⁸Yu, D. T. Y., Clements, P. J., Paulus, H. E., Peter, J. B., Levy, J., and Barnett, E. V. (1974). Human lymphocyte subpopulations: effect of corticosteroids. *Journal of Clinical Investigation*, **53**, 565–571.
- ²⁹Rinehart, J. J., Sagone, A. L., Balcerzak, S. P., Ackerman, G. A., and LoBuglio, A. F. (1975). Effects of corticosteroid therapy on human monocyte function. *New England Journal of Medicine*, **292**, 236–241.
- ³⁰Andersen, V., Bro-Rasmussen, F., and Hougaard, K. (1969). Autoradiographic studies of eosinophil kinetics: effects of cortisol. *Cell and Tissue Kinetics*, **2**, 139–146.

- ³¹Webel, M. L., Ritts, R. E., Jr., Taswel, H. F., Donadio, J. V., Jr., and Woods, J. E. (1974). Cellular immunity after intravenous administration of methylprednisolone. *Journal of Laboratory and Clinical Medicine*, **83**, 383-392.
- ³²Fauci, A. S., and Dale, D. C. (1975). Alternate-day prednisone therapy and human lymphocyte sub-populations. *Journal of Clinical Investigation*, **55**, 22-32.
- ³³Boggs, D. R., Athens, J. W., Cartwright, G. E., and Wintrobe, M. M. (1964). The effect of adrenal corticosteroids upon the cellular composition of inflammatory exudates. *American Journal of Pathology*, **44**, 763-773.
- ³⁴Ward, P. A. (1966). The chemosuppression of chemotaxis. *Journal of Experimental Medicine*, **124**, 209-226.
- ³⁵Grant, L., Palmer, P., and Sanders, A. G. (1962). The effect of heparin on the sticking of white cells to endothelium in inflammation. *Journal of Pathology and Bacteriology*, **83**, 127-133.
- ³⁶Rinehart, J. J., Balcerzak, S. P., Sagone, A. L., and LoBuglio, A. F. (1974). Effects of corticosteroids on human monocyte function. *Journal of Clinical Investigation*, **54**, 1337-1343.
- ³⁷Balow, J. E., and Rosenthal, A. S. (1973). Glucocorticoid suppression of macrophage migration inhibitory factor. *Journal of Experimental Medicine*, **137**, 1031-1041.
- ³⁸Weston, W. L., Claman, H. N., and Krueger, G. G. (1973). Sites of action of cortisol in cellular immunity. *Journal of Immunology*, **110**, 880-883.
- ³⁹Wahl, S. M., Altman, L. C., and Rosenstreich, D. L. (1975). Inhibition of *in vitro* lymphokine synthesis by glucocorticosteroids. *Journal of Immunology*, **115**, 476-481.
- ⁴⁰Fauci, A. S., and Dale, D. C. (1975). The effect of hydrocortisone on the kinetics of normal human lymphocytes. *Blood*, **46**, 235-243.
- ⁴¹Fauci, A. S. (1976). Mechanisms of corticosteroid action on lymphocyte sub-populations. 2. Differential effects of *in vivo* hydrocortisone, prednisone and dexamethasone on *in vitro* expression of lymphocyte function. *Clinical and Experimental Immunology*, **24**, 54-62.
- ⁴²Balow, J. E., Hurley, D. L., and Fauci, A. S. (1975). Immunosuppressive effects of glucocorticosteroids: differential effects of acute vs chronic administration on cell-mediated immunity. *Journal of Immunology*, **114**, 1072-1076.
- ⁴³Fauci, A. S., and Dale, D. C. (1974). The effect of *in vivo* hydrocortisone on sub-populations of human lymphocytes. *Journal of Clinical Investigation*, **53**, 240-246.
- ⁴⁴Craddock, C. G., Winkelstein, A., Matsuyuki, Y., and Lawrence, J. S. (1976). The immune response to foreign red blood cells and the participation of short-lived lymphocytes. *Journal of Experimental Medicine*, **125**, 1149-1172.
- ⁴⁵Stavy, L. Cohen, I. R., and Feldman, M. (1973). The effect of hydrocortisone on lymphocyte-mediated cytotoxicity. *Cellular Immunology*, **7**, 302-312.
- ⁴⁶Werdelin, O., and McCluskey, R. T. (1971). The nature and the specificity of mononuclear cells in experimental autoimmune inflammations and the mechanisms leading to their accumulation. *Journal of Experimental Medicine*, **133**, 1242-1263.
- ⁴⁷Atkinson, J. P., Schreiber, A. D., and Frank, M. M. (1973). Effect of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes. *Journal of Clinical Investigation*, **52**, 1509-1517.
- ⁴⁸Schayer, R. W. (1963). Induced synthesis of histamine, microcirculatory regulation and the mechanism of action of the adrenal glucocorticoid hormones. *Progress in Allergy*, **7**, 187-212.
- ⁴⁹Butler, W. T. (1975). Corticosteroids and immunoglobulin synthesis. *Transplantation Proceedings*, **7**, 49-53.
- ⁵⁰Atkinson, J. P., and Frank, M. M. (1973). Effect of cortisone therapy on serum complement components. *Journal of Immunology*, **111**, 1061-1066.
- ⁵¹Zweifach, B. W., Shorr, E., and Black, M. M. (1953). The influence of the adrenal cortex on behaviour of terminal vascular bed. *Annals of the New York Academy of Science*, **56**, 626-633.
- ⁵²Suddick, R. P. (1966). Glucocorticoid-kinin antagonism in the rat. *American Journal of Physiology*, **211**, 844-850.
- ⁵³Baxter, J. D., and Forsham, P. H. (1972). Tissue effects of glucocorticoids. *American Journal of Medicine*, **53**, 573-589.
- ⁵⁴Cutroneo, K. R., and Counts, D. F. (1975). Anti-inflammatory steroids and collagen metabolism, glucocorticoid-mediated alterations of prolyl hydroxylase activity and collagen synthesis. *Molecular Pharmacology*, **11**, 632-639.
- ⁵⁵Smith, C. I., Cooksley, W. G. E., and Powell, L. W. (1977). Immunological abnormalities

- associated with liver disease: cause or effect? *Australian and New Zealand Journal of Medicine*, **7**, 604–612.
- ⁵⁶Cochrane, A. M. G., Moussouros, A., Portmann, B., McFarlane, I. G., Thomson, A. D., Eddleston, A. L. W., and Williams, R. (1977). Lymphocyte cytotoxicity for isolated hepatocytes in alcoholic liver disease. *Gastroenterology*, **72**, 918–923.
- ⁵⁷Ferluga, J., and Allison, A. C. (1978). Role of mononuclear infiltrating cells in pathogenesis of hepatitis. *Lancet*, **2**, 610–611.
- ⁵⁸Cook, J. A., and DiLuzio, N. R. (1973). Protective effect of cysteine and methylprednisolone in lead acetate-endotoxin induced shock. *Experimental and Molecular Pathology*, **19**, 127–138.
- ⁵⁹Weiersmüller, A., Colombo, J. P., and Bircher, J. (1977). The influence of prednisolone on hepatic function in normal subjects. *American Journal of Digestive Diseases*, **22**, 424–428.
- ⁶⁰Huber, T. E., and Wiley, A. T. (1955). Cortisone in the treatment of infectious hepatitis. *Annals of Internal Medicine*, **42**, 1011–1024.
- ⁶¹Ducci, H., and Katz, R. (1952). Cortisone, ACTH and antibiotics in fulminant hepatitis. *Gastroenterology*, **21**, 357–374.
- ⁶²Evans, A. S., Sprinz, H., and Nelson, R. S. (1953). Adrenal hormone therapy in viral hepatitis. 2. The effect of cortisone in the acute disease. *Annals of Internal Medicine*, **38**, 1134–1147.
- ⁶³Blum, A. L., Stutz, R., Haemmerli, U. P., Schmid, P., and Grady, G. F. (1969). A fortuitously controlled study of steroid therapy in acute viral hepatitis. *American Journal of Medicine*, **47**, 82–92.
- ⁶⁴Shaldon, S., and Sherlock, S. (1957). Virus hepatitis with features of prolonged bile retention. *British Medical Journal*, **2**, 734–738.
- ⁶⁵Lipschutz, E. W., and Capson, D. (1955). “Cholangiolitic hepatitis”, with special reference to its physiopathologic concept, diagnosis and therapy. *Annals of Internal Medicine*, **43**, 1037–1047.
- ⁶⁶Goldgraber, M. B., and Kirsner, J. B. (1959). The use of adrenal steroids in subacute and chronic cholangiolitic hepatitis. *Archives of Internal Medicine*, **103**, 354–368.
- ⁶⁷De Ritis, F., Giusti, G., Mallucci, L., and Piazza, M. (1964). Negative results of prednisone therapy in viral hepatitis (letter). *Lancet*, **1**, 533–534.
- ⁶⁸Katz, R., Velasco, M., Klinger, J., and Alessandri, H. (1962). Corticosteroids in the treatment of acute hepatitis in coma. *Gastroenterology*, **42**, 258–265.
- ⁶⁹Rueff, B., and Behamou, J. P. (1973). Acute hepatic necrosis and fulminant hepatic failure. *Gut*, **14**, 805–815.
- ⁷⁰Ware, A. J., Jones, R. E., Shorey, J. W., and Combes, B. (1974). A controlled trial of steroid therapy in massive hepatic necrosis. *American Journal of Gastroenterology*, **62**, 130–133.
- ⁷¹Redeker, A. G., Schweitzer, I. L., and Yamahiro, H. S. (1976). Randomization of corticosteroid therapy in fulminant hepatitis. (Letter) *New England Journal of Medicine*, **294**, 728–729.
- ⁷²Gregory, P. B., Knauer, C. M., Kempson, R. L., and Miller, R. (1976). Steroid therapy in severe viral hepatitis. *New England Journal of Medicine*, **294**, 681–687.
- ⁷³Mosley, J. W., Combes, B., Volwiler, W., and Zimmerman, H. J. (1976). Corticosteroids in fulminant hepatitis. (Letter) *New England Journal of Medicine*, **295**, 898–899.
- ⁷⁴Acute Hepatic Failure Study Group (1979). A double-blinded, randomized trial of hydrocortisone in acute hepatic failure (Abstract). *Gastroenterology*, **76**, 1297.
- ⁷⁵Report from the European Association for the Study of the Liver (EASL) (1979). Randomized trial of steroid therapy in acute liver failure. *Gut*, **20**, 620–623.
- ⁷⁶Cook, G. C., Mulligan, R., and Sherlock, S. (1971). Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. *Quarterly Journal of Medicine*, **40**, 159–185.
- ⁷⁷Murray-Lyon, I. M., Stern, R. B., and Williams, R. (1973). Controlled trial of prednisone and azathioprine in active chronic hepatitis. *Lancet*, **1**, 735–737.
- ⁷⁸Soloway, R. D., Summerskill, W. H. J., Baggenstoss, A. H., Geall, M. G., Gitnick, G. L., Elveback, L. R., and Schoenfeld, L. J. (1972). Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. *Gastroenterology*, **63**, 820–833.
- ⁷⁹Smith, M. G. M., Golding, P. L., Eddleston, A. L. W. F., Mitchell, C. G., Kemp, A., and Williams, R. (1972). Cell-mediated immune responses in chronic liver diseases. *British Medical Journal*, **1**, 527–530.

- ⁸⁰Meyer zum Büschenfelde, K. H., Knolle, J., and Berger, J. (1974). Celluläre Immunreaktionen gegenüber homologen leberspezifischen Antigenen (HLP) bei chronischen Leberentzündungen. *Klinische Wochenschrift*, **52**, 246–248.
- ⁸¹Miller, J., Smith, M. G. M., Mitchell, C. G., Reed, W. D., Eddleston, A. L. W. F., and Williams, R. (1972). Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. *Lancet*, **2**, 296–297.
- ⁸²Dudley, F. J., Fox, R. A., and Sherlock, S. (1972). Cellular immunity and hepatitis-associated, Australia antigen liver disease. *Lancet*, **1**, 723–726.
- ⁸³Lam, K. C., and Lai, C. L. (1978). Controlled prospective study on the effect of prednisolone in HBsAg-positive chronic active hepatitis. (Abstract) *EASL*, 65.
- ⁸⁴Summerskill, W. H. J., Korman, M. G., Ammon, H. V., and Baggenstoss, A. H. (1975). Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. *Gut*, **16**, 876–883.
- ⁸⁵Plotz, P. H. (1975). Asymptomatic chronic hepatitis. *Gastroenterology*, **68**, 1629–1630.
- ⁸⁶Wright, E. C., Seeff, L. B., Berk, P. D., Jones, E. A., and Plotz, P. H. (1977). Treatment of chronic active hepatitis: an analysis of three controlled trials. *Gastroenterology*, **73**, 1422–1430.
- ⁸⁷Summerskill, W. H. J. (1974). Chronic active liver disease re-examined: prognosis hopeful. *Gastroenterology*, **66**, 450–464.
- ⁸⁸Czaja, A. J., and Summerskill, W. H. J. (1978). Chronic hepatitis: to treat or not to treat? *Medical Clinics of North America*, **62**, 71–85.
- ⁸⁹Kirk, A. P., Jain, S., Pocock, S., Thomas, H. C., and Sherlock, S. (1979). Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in chronic active hepatitis (Abstract). *Gut*, **20**, A449.
- ⁹⁰Becker, M. D., Scheuer, P. J., Baptista, A., and Sherlock, S. (1970). Prognosis of chronic persistent hepatitis. *Lancet*, **1**, 53–57.
- ⁹¹Chadwick, R. G., Galizzi, J. Jr., Heathcote, J., Lyssiotis, T., Cohen, B. J., Scheuer, P. J., and Sherlock, S. (1979). Chronic persistent hepatitis: hepatitis B virus markers and histological follow-up. *Gut*, **20**, 372–377.
- ⁹²Zetterman, R. K., Luisada-Opper, A., and Leevy, C. M. (1976). Alcoholic hepatitis: cell-mediated immunological response to alcoholic hyaline. *Gastroenterology*, **70**, 382–384.
- ⁹³Snyder, N., Bessoff, J., Dwyer, J. M., and Conn, H. O. (1978). Depressed delayed cutaneous hypersensitivity in alcoholic hepatitis. *American Journal of Digestive Diseases*, **23**, 353–358.
- ⁹⁴Campra, J. L., Hamlin, E. M., Jr., Kirshbaum, R. J., Oliver, M., Redeker, A. G., and Reynolds, T. B. (1973). Prednisone therapy of acute alcoholic hepatitis: report of a controlled trial. *Annals of Internal Medicine*, **79**, 625–631.
- ⁹⁵Helman, R. A., Temko, M. H., Nye, S. W., and Fallon, H. J. (1971). Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. *Annals of Internal Medicine*, **74**, 311–321.
- ⁹⁶Porter, H. P., Simon, F. R., Pope, C. E., Volwiler, W., and Fenster, L. F. (1971). Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. *New England Journal of Medicine*, **284**, 1350–1355.
- ⁹⁷Blitzer, B. L., Mutchnick, M. G., Joshi, P. H., Phillips, D. P., Fessel, J. M., and Conn, H. O. (1977). Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. *American Journal of Digestive Diseases*, **22**, 477–484.
- ⁹⁸Shumaker, J. B., Resnick, R. H., Galambos, J. T., and Iber, F. L. (1974). Steroids in alcoholic hepatitis: survival related to biopsy feasibility (Abstract). *Gastroenterology*, **66**, 778.
- ⁹⁹Lesesne, H. R., Bozymski, E. M., and Fallon, H. J. (1978). Treatment of alcoholic hepatitis with encephalopathy. *Gastroenterology*, **74**, 169–173.
- ¹⁰⁰Maddrey, W. C., Boitnott, J. K., Bedine, M. S., Weber, F. L., Jr., Mezey, E., and White, R. I., Jr. (1978). Corticosteroid therapy of alcoholic hepatitis. *Gastroenterology*, **75**, 193–199.
- ¹⁰¹Depew, W. T., Boyer, T. D., Omata, N., Redeker, A. G., and Reynolds, T. B. (1978). Double-blind controlled trial of corticosteroid therapy in severe alcoholic hepatitis with encephalopathy. *Clinical Research*, **26**, 150A.
- ¹⁰²Conn, H. O. (1978). Steroid treatment of alcoholic hepatitis: the yeas and the nays. *Gastroenterology*, **74**, 319–322.
- ¹⁰³Powell, L. W., and Tolman, K. G. (1979). Treatment of inflammatory and metal storage diseases of the liver. *Clinics in Gastroenterology*, **8**, 69–88.

- ¹⁰⁴Sherlock, S., Datta, D. V., and Walker, J. G. (1966). Prognosis and treatment of primary biliary cirrhosis. *Revue Internationale d'Hépatologie*, **16**, 217–225.
- ¹⁰⁵Long, R. G., Meinhard, E., Skinner, R. K., Varghese, Z., Wills, M. R., and Sherlock, S. (1978). Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease. *Gut*, **19**, 85–90.
- ¹⁰⁶Farrell, G. C., and Powell, L. W. (1976). Chronic granulomatous hepatitis. *Australian and New Zealand Journal of Medicine*, **6**, 474–478.
- ¹⁰⁷Israel, H. L., and Goldstein, R. A. (1973). Hepatic granulomatosis and sarcoidosis. *Annals of Internal Medicine*, **79**, 669–678.
- ¹⁰⁸Simon, H. B., and Wolff, S. M. (1973). Granulomatous hepatitis and prolonged fever of unknown origin: a study of 13 patients. *Medicine*, **52**, 1–21.